Please use this identifier to cite or link to this item: http://hdl.handle.net/11054/3347
Title: Salvage therapies for recurrent grade 4 IDH-wildtype glioma: A BRAIN Registry analysis of real-world treatment patterns.
Author: Sanderson, E.
Drummond, K.
Dowling, A.
Bennett, I.
Freilich, R.
Phillips, C.
Ahern, E.
Campbell, D.
Campbell, R.
Harrup, R.
Reeves, Simone
Collins, I.
Jennens, R.
Joshi, S.
Gan, H.
Fay, M.
Lynam, J.
Lim, Lisi E.
Rosenthal, M.
Dumas, M.
Gibbs, P.
Gately, L.
Issue Date: 2026
Publication Title: Journal of Neuro-Oncology
Volume: 179
Start Page: 13
Abstract: Purpose: The prognosis for patients with glioblastoma after failure of first-line therapy is poor. Despite this, the standard of care for patients with recurrent disease is not well-defined. Here we report on the use of salvage therapies in glioblastoma using real-world data. Methods: Data were extracted from the BRAIN Registry for patients diagnosed with glioblastoma (Grade 4, IDH wild-type) between 09/2019 and 01/2024. Only patients who received salvage therapies following a documented date of recurrence/progression were included. Relevant descriptive and intergroup statistics were used, with survival calculated using Kaplan-Meier and Cox regression used for multivariate analyses. Results: 275 patients were identified. Median age was 61 (range:23–88) years, with 56% being ECOG 0–1 at recurrence. Median time to progression was 7.6 months with 65% recurring/progressing during first-line therapy. Systemic therapy (85%) was most utilised with 67% receiving single-agent bevacizumab. Outcomes in this subgroup were similar to clinical trial data. 29% patients underwent re-resection with 58% of these then receiving systemic treatment. Compared with no surgery, patients who underwent re-resection were younger (p = 0.02), of better performance status (p = 0.006) and more likely to have recurred post completing first-line therapy (p = 0.001). Few patients (n = 9) received re-irradiation with median of 15 months between radiation events. Median post-progression survival (PPS) was 9.5 months. After adjustment for confounders, there was no difference in PPS for patients who underwent re-resection versus systemic therapy alone (p = 0.242). The survival differences observed between treatment modalities likely reflect patient factors influencing treatment selection and were impacted by small subgroup sizes. Conclusion: Systemic therapy is most utilised in the salvage setting, predominantly bevacizumab. Certain patient characteristics were associated with re-resection. Re-irradiation was rarely used. Clinical trial number: ACTRN12618001959268.
URI: http://hdl.handle.net/11054/3347
DOI: https://doi.org/10.1007/s11060-026-05717-x
Internal ID Number: 03299
Health Subject: GLIOBLASTOMA
RECURRENCE
TREATMENT PATTERNS
SALVAGE THERAPIES
Type: Journal Article
Article
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.